Drug Research
Drug Discovery & Development

Drug Discovery & Development News

View news from other Pharmaceutical sectors:
211-225 of 4724 results
Aviragen Therapeutics and Vaxart sign merger deal
By PBR Staff Writer
Aviragen Therapeutics, which is engaged in the discovery and development of direct-acting antivirals to treat infections with limited therapeutic options, has signed a merger agreement with Vaxart, a clinical-stage company focused on developing oral recombinant vaccines.
Drug Research > Drug Discovery & Development > News
Voyager to gain global rights to VY-AADC program for advanced Parkinson’s disease
Voyager Therapeutics, a clinical-stage gene therapy company focused on developing treatments for severe neurological diseases, has announced an update to its VY-AADC program for advanced Parkinson’s disease.
Drug Research > Drug Discovery & Development > News
Researchers identify new genetic variants for breast cancer risk
A major international collaboration involving hundreds of researchers worldwide has identified seventy-two new genetic variants that contribute to the risk of developing breast cancer.
Drug Research > Drug Discovery & Development > News
Incyte, MacroGenics sign licensing agreement for anti-PD-1 monoclonal antibody MGA012
Incyte and MacroGenics have entered into an exclusive global collaboration and license agreement for MacroGenics’ MGA012, an investigational monoclonal antibody that inhibits programmed cell death protein 1 (PD-1).
Drug Research > Drug Discovery & Development > News
AbbVie, Alector to develop novel treatments for Alzheimer's disease
By PBR Staff Writer
AbbVie has collaborated with Alector to develop and commercialize new treatments for Alzheimer's disease and other neurodegenerative disorders.
Drug Research > Drug Discovery & Development > News
Aurinia to expand voclosoprin renal franchise
Aurinia Pharmaceuticals revealed plans to expand its voclosoprin renal franchise to include focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD).
Drug Research > Drug Discovery & Development > News
Boehringer Ingelheim partners with TARGET to progress NASH research
TARGET PharmaSolutions announced that Boehringer Ingelheim International has entered into a multi-year strategic partnership for TARGET-NASH.
Drug Research > Drug Discovery & Development > News
Alnylam, Vir to jointly advance RNAi therapeutics for infectious diseases
Alnylam Pharmaceuticals has announced an exclusive licensing agreement with Vir Biotechnology for the development and commercialization of RNAi therapeutics for infectious diseases, including chronic hepatitis B virus (HBV) infection.
Drug Research > Drug Discovery & Development > News
Takeda, HemoShear collaborate to develop drugs for liver diseases
By PBR Staff Writer
Takeda has collaborated with HemoShear Therapeutics to discover and develop novel therapeutics for liver diseases such as nonalcoholic steatohepatitis (NASH).
Drug Research > Drug Discovery & Development > News
Moleculin to collaborate with University of Bergen for immune stimulation drug
Moleculin Biotech has entered into an agreement to collaborate with the University of Bergen to expand research on inhibition of brain metastasis by its pre-clinical drug WP1066 and its ability to increase immune system response to cancer and suppression of tumor cell proliferation and survival.
Drug Research > Drug Discovery & Development > News
Moffitt researchers discover new targets for approved cancer drug
A team of researchers at Moffitt Cancer Center used cellular drug screening, functional proteomics and computer-based modeling to determine whether drugs with well-known targets may be repurposed for use against other biological targets.
Drug Research > Drug Discovery & Development > News
PanOptica secures $11m to advance clinical development novel topical anti-VEGF eye drop
PanOptica a private biopharmaceutical company focused on developing innovative ophthalmology therapies, announced that it has secured $11m in a series B financing.
Drug Research > Drug Discovery & Development > News
Visterra closes $46.7m series C financing to advance pipeline of precision antibody-based biological medicines
Visterra has completed a series C financing round raising a total of $46.7m, including a new extension totaling $23.6m.
Drug Research > Drug Discovery & Development > News
Ligand to acquire Crystal Bioscience
Ligand Pharmaceuticals has announced the signing of a merger agreement whereby Ligand will acquire Crystal, a leader in avian genetics and the generation of fully-human therapeutic antibodies.
Drug Research > Drug Discovery & Development > News
Recursion Pharmaceuticals raises $60m to industrialize drug discovery using artificial intelligence
Recursion Pharmaceuticals, a biotechnology company that combines innovative biological science with artificial intelligence to discover new therapeutics at scale, is announcing its $60m series B financing led by Data Collective (DCVC).
Drug Research > Drug Discovery & Development > News
211-225 of 4724 results